LIFR and hepatocellular carcinoma: Evidence has shown that sorafenib resistance is closely associated with ferroptosis in HCC, and several signaling pathways, including Wnt/β-catenin/ferroptosis axis, Hippo/YAP signaling axis, LIFR/NF-κB/LCN2 pathway, and Nrf2/HO-1/GPX4 axis, are also involved, revealing the complicated mechanisms of sorafenib-associated ferroptosis suppression in HCC [32,44,45].